SCH-442,416
SCH-442,416 structure|thumb SCH-442,416 stands out as a significant molecule in the realm of neurological pharmacology. This compound specifically targets the adenosine A2a subtype receptor, acting as an antagonist. The potency and selectivity of SCH-442,416 have implications not only for clinical treatments but also for advanced scientific investigations into the workings of the human brain.
Chemical and Biological Characteristics
SCH-442,416, by design, is a highly selective antagonist for the adenosine A2a subtype receptor[1]. It has been utilized in its 11C radiolabelled form, which facilitates mapping the distribution of A2a receptors within the brain.
Distribution of A2a Receptors in the Brain
The A2a receptors, identified via the radiolabelled form of SCH-442,416, are prominently found in:
Striatum Nucleus accumbens Olfactory tubercle These regions play critical roles in movement, reward processing, and olfaction[2].
Therapeutic Implications
Given the distribution of A2a receptors in the brain, there is immense interest in harnessing their potential for therapeutic applications. SCH-442,416, in particular, has shown therapeutic promise in several neurological disorders:
- Depression: Studies suggest that modulation of A2a receptors might have antidepressant effects, with SCH-442,416 showing potential efficacy[3].
- Parkinson's disease: Given the prominent location of A2a receptors in movement-associated regions like the striatum, SCH-442,416 is being researched for its potential in Parkinson's disease treatment[4].
- Catalepsy: The antagonist properties of SCH-442,416 have demonstrated efficacy in reducing cataleptic behaviors in experimental models[5].
Future Perspectives
The unique properties and potentials of SCH-442,416 necessitate further research, both for therapeutic applications and for deepening our understanding of the brain's intricate networks. As research advances, the role of adenosine A2a receptors in health and disease will undoubtedly become even clearer.
External links
References
- Jacobson, K. A., & Gao, Z. G. (2006). Adenosine receptors as therapeutic targets. Nature Reviews Drug Discovery, 5(3), 247-264.
- Fink, J. S., Weaver, D. R., Rivkees, S. A., Peterfreund, R. A., Pollack, A. E., Adler, E. M., & Reppert, S. M. (1992). Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain research. Molecular brain research, 14(3), 186-195.
- El Yacoubi, M., Ledent, C., Parmentier, M., Costentin, J., & Vaugeois, J. M. (2001). Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice. British journal of pharmacology, 134(1), 68-77.
- Pinna, A. (2014). Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued. CNS drugs, 28(5), 455-474.
- Ferré, S., Ciruela, F., Borycz, J., Solinas, M., Quarta, D., Antoniou, K., ... & Lluis, C. (2008). Adenosine A1-A2A receptor heteromers: new targets for caffeine in the brain. Frontiers in bioscience: a journal and virtual library, 13, 2391-2399.
- ↑ Jacobson, K. A., & Gao, Z. G. (2006). Adenosine receptors as therapeutic targets. Nature Reviews Drug Discovery, 5(3), 247-264.
- ↑ Fink, J. S., Weaver, D. R., Rivkees, S. A., Peterfreund, R. A., Pollack, A. E., Adler, E. M., & Reppert, S. M. (1992). Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain research. Molecular brain research, 14(3), 186-195.
- ↑ El Yacoubi, M., Ledent, C., Parmentier, M., Costentin, J., & Vaugeois, J. M. (2001). Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice. British journal of pharmacology, 134(1), 68-77.
- ↑ Pinna, A. (2014). Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued. CNS drugs, 28(5), 455-474.
- ↑ Ferré, S., Ciruela, F., Borycz, J., Solinas, M., Quarta, D., Antoniou, K., ... & Lluis, C. (2008). Adenosine A1-A2A receptor heteromers: new targets for caffeine in the brain. Frontiers in bioscience: a journal and virtual library, 13, 2391-2399.
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD